VIR 2981
Alternative Names: VIR-2981Latest Information Update: 08 May 2024
At a glance
- Originator Vir Biotechnology
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Neuraminidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Influenza A virus infections; Influenza B virus infections
Most Recent Events
- 22 Feb 2024 Vir Biotechnology plans to file IND for Influenza A and B virus infections within next 18 months
- 17 Aug 2023 Vir Biotechnology has patent pending for "Broadly neutralizing antibodies against influenza neuraminidase" in Australia, Canada, Israel, and Taiwan
- 20 Jul 2023 Pharmacodynamics data from a preclinical study in Influenza A virus infections and Influenza B virus infections released by Vir Biotechnology